dc.contributor.author | Twelves, CJ | |
dc.contributor.author | Dobbs, NA | |
dc.contributor.author | Curnow, Alison | |
dc.contributor.author | Coleman, RE | |
dc.contributor.author | Stewart, AL | |
dc.contributor.author | Tyrrell, CJ | |
dc.contributor.author | Canney, P | |
dc.contributor.author | Rubens, RD | |
dc.date.accessioned | 2016-01-11T11:39:55Z | |
dc.date.issued | 1994-11 | |
dc.description.abstract | Thirty-four evaluable patients were treated with vinorelbine, a novel, semisynthetic vinca alkaloid, as first-line chemotherapy for advanced breast cancer. They received vinorelbine 25 mg m-2 i.v. given weekly for a maximum of 16 cycles. Two patients achieved a complete remission and 15 a partial remission, giving a response rate of 17/34 (50%; 95% CI of 34-66%); median response duration was 5.8 months. The median progression-free interval was 4.4 months and median survival 9.9 months. Treatment was generally well tolerated. Fatigue was the most common side-effect. The main reason for dose adjustments was myelosuppression; 68% of patients had WHO grade 3 or 4 neutropenia and there was one death attributed to neutropenic sepsis. Nausea/vomiting and neuropathy were mild and alopecia was uncommon. This study confirms vinorelbine as a highly active, well-tolerated agent in advanced breast cancer worthy of evaluation in combination chemotherapy regimens. | en_GB |
dc.identifier.citation | Vol. 70, pp. 990 - 993 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/19201 | |
dc.language.iso | en | en_GB |
dc.publisher | Cancer Research UK | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/7947109 | en_GB |
dc.rights | Article available under a Creative Commons Attribution Non-Commercial Share Alike License. | en_GB |
dc.subject | Adult | en_GB |
dc.subject | Aged | en_GB |
dc.subject | Antineoplastic Agents | en_GB |
dc.subject | Breast Neoplasms | en_GB |
dc.subject | Breast Neoplasms, Male | en_GB |
dc.subject | Dose-Response Relationship, Drug | en_GB |
dc.subject | Drug Administration Schedule | en_GB |
dc.subject | Female | en_GB |
dc.subject | Follow-Up Studies | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Male | en_GB |
dc.subject | Middle Aged | en_GB |
dc.subject | Vinblastine | en_GB |
dc.title | A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2016-01-11T11:39:55Z | |
dc.identifier.issn | 0007-0920 | |
exeter.place-of-publication | SCOTLAND | |
dc.description | Clinical Trial, Phase II | en_GB |
dc.description | Multicenter Study | en_GB |
dc.description | Full text is available as a scanned copy of the original print version | en_GB |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.journal | British Journal of Cancer | en_GB |
dc.identifier.pmid | 7947109 | |